Education
About Us
Working with TipRanks
Follow Us
Royalty Pharma PLC (RPRX)
NASDAQ:RPRX
Earnings Data
Report Date
Feb 17, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
1.27Last Year’s EPS
1.15Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
Royalty Pharma reported a strong financial performance with significant growth and strategic acquisitions in the third quarter of 2025, leading to an upward revision of its full-year guidance. Despite challenges such as the upcoming decline in Promacta royalties and increased interest expenses, the company's diversified portfolio and pipeline expansion underline its growth potential.Company Guidance
Strong Financial Performance
Royalty Pharma reported an 11% growth in both portfolio receipts and royalty receipts, driven by a diversified portfolio. The company raised its full-year 2025 guidance for portfolio receipts to $3.2 billion to $3.25 billion, representing growth of 14% to 16%.
Successful Capital Deployment
The company deployed $1 billion in the quarter on loyalty transactions, totaling $1.7 billion for the first 9 months. It also repurchased 4 million shares, totaling $1.15 billion in share repurchases for the year.
Strategic Acquisitions
Acquired royalty interests in Amgen's Imdelltra for up to $950 million, Zenas Biopharma's obexelimab for up to $300 million, and Alnylam's Amvuttra for $310 million.
Pipeline Expansion
Development-stage pipeline expanded to 17 therapies, with expectations of multiple pivotal readouts in the near future. The pipeline is expected to generate over $36 billion in cumulative peak sales.
Consistent Returns
Return on invested capital maintained at 15.7% and return on invested equity at 22.9%.
RPRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RPRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 05, 2025 | $37.84 | $40.42 | +6.82% |
Aug 06, 2025 | $37.68 | $36.90 | -2.07% |
May 08, 2025 | $32.34 | $32.68 | +1.05% |
Feb 11, 2025 | $31.11 | $31.63 | +1.67% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Royalty Pharma PLC (RPRX) report earnings?
Royalty Pharma PLC (RPRX) is schdueled to report earning on Feb 17, 2026, Before Open (Confirmed).
What is Royalty Pharma PLC (RPRX) earnings time?
Royalty Pharma PLC (RPRX) earnings time is at Feb 17, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RPRX EPS forecast?
RPRX EPS forecast for the fiscal quarter 2025 (Q4) is 1.27.